Prions: Protein Aggregation and Infectious Diseases - Physiological ...

1142 ADRIANO AGUZZI AND ANNA MARIA CALELLA
79. Bruce ME, McBride PA, Farquhar CF. Precise targeting of the
pathology of the sialoglycoprotein, PrP, vacuolar degeneration in
mouse scrapie. Neurosci Lett 102: 1–6, 1989.
80. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D,
Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S,
Fraser H, Bostock CJ. Transmissions to mice indicate that “new
variant” CJD is caused by the BSE agent. Nature 389: 498–501,
1997.
81. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L,
Zurdo J, Taddei N, Ramponi G, Dobson CM, Stefani M. Inherent
toxicity of aggregates implies a common mechanism for protein
misfolding diseases. Nature 416: 507–511, 2002.
82. Buchanan CR, Preece MA, Milner RD. Mortality, neoplasia, and
Creutzfeldt-Jakob disease in patients treated with human pituitary
growth hormone in the United Kingdom. BMJ 302: 824–828, 1991.
83. Büeler H, Raeber A, Sailer A, Fischer M, Aguzzi A, Weissmann
C. High prion and PrPSc levels but delayed onset of disease
in scrapie-inoculated mice heterozygous for a disrupted PrP gene.
Mol Med 1: 19–30, 1994.
84. Büeler HR, Aguzzi A, Sailer A, Greiner RA, Autenried P,
Aguet M, Weissmann C. Mice devoid of PrP are resistant to
scrapie. Cell 73: 1339–1347, 1993.
85. Büeler HR, Fischer M, Lang Y, Bluethmann H, Lipp HP, De-
Armond SJ, Prusiner SB, Aguet M, Weissmann C. Normal
development and behaviour of mice lacking the neuronal cellsurface
PrP protein. Nature 356: 577–582, 1992.
86. Burwinkel M, Schwarz A, Riemer C, Schultz J, Van Landeghem
F, Baier M. Rapid disease development in scrapie-infected
mice deficient for CD40 ligand. EMBO Rep 5:527–531, 2004.
87. Buschmann A, Biacabe AG, Ziegler U, Bencsik A, Madec JY,
Erhardt G, Luhken G, Baron T, Groschup MH. Atypical scrapie
cases in Germany and France are identified by discrepant reaction
patterns in BSE rapid tests. J Virol Methods 117: 27–36, 2004.
88. Calzolai L, Lysek DA, Perez DR, Guntert P, Wüthrich K. Prion
protein NMR structures of chickens, turtles, and frogs. Proc Natl
Acad Sci USA 102: 651–655, 2005.
89. Canello T, Engelstein R, Moshel O, Xanthopoulos K, Juanes
ME, Langeveld J, Sklaviadis T, Gasset M, Gabizon R. Methionine
sulfoxides on PrPSc: a prion-specific covalent signature. Biochemistry
47: 8866–8873, 2008.
90. Carp RI. Transmission of scrapie by oral route: effect of gingival
scarification. Lancet 1: 170–171, 1982.
91. Cashman NR, Loertscher R, Nalbantoglu J, Shaw I, Kascsak
RJ, Bolton DC, Bendheim PE. Cellular isoform of the scrapie
agent protein participates in lymphocyte activation. Cell 61: 185–
192, 1990.
92. Castilla J, Gonzalez-Romero D, Saa P, Morales R, De Castro
J, Soto C. Crossing the species barrier by PrP(Sc) replication in
vitro generates unique infectious prions. Cell 134: 757–768, 2008.
93. Castilla J, Morales R, Saa P, Barria M, Gambetti P, Soto C.
Cell-free propagation of prion strains. EMBO J 27: 2557–2565, 2008.
94. Castilla J, Saa P, Hetz C, Soto C. In vitro generation of infectious
scrapie prions. Cell 121: 195–206, 2005.
95. Castilla J, Saa P, Soto C. Detection of prions in blood. Nat Med
11: 982–985, 2005.
96. Caughey B, Baron GS, Chesebro B, Jeffrey M. Getting a grip on
prions: oligomers, amyloids, and pathological membrane interactions.
Annu Rev Biochem 78: 177–204, 2009.
97. Caughey B, Horiuchi M, Demaimay R, Raymond GJ. Assays of
protease-resistant prion protein and its formation. Methods Enzymol
309: 122–133, 1999.
98. Caughey B, Race RE. Potent inhibition of scrapie-associated PrP
accumulation by congo red. J Neurochem 59: 768–771, 1992.
99. Caughey B, Raymond GJ. The scrapie-associated form of PrP is
made from a cell surface precursor that is both protease- and
phospholipase-sensitive. J Biol Chem 266: 18217–18223, 1991.
100. Caughey B, Raymond GJ. Sulfated polyanion inhibition of
scrapie-associated PrP accumulation in cultured cells. J Virol 67:
643–650, 1993.
101. Caughey B, Raymond GJ, Bessen RA. Strain-dependent differences
in beta-sheet conformations of abnormal prion protein.
J Biol Chem 273: 32230–32235, 1998.
Physiol Rev VOL 89 OCTOBER 2009 www.prv.org
102. Caughey B, Raymond LD, Raymond GJ, Maxson L, Silveira J,
Baron GS. Inhibition of protease-resistant prion protein accumulation
in vitro by curcumin. J Virol 77: 5499–5502, 2003.
103. Caughey BW, Dong A, Bhat KS, Ernst D, Hayes SF, Caughey
WS. Secondary structure analysis of the scrapie-associated protein
PrP 27–30 in water by infrared spectroscopy. Biochemistry 30: 7672–
7680, 1991.
104. Caughey WS, Raymond LD, Horiuchi M, Caughey B. Inhibition
of protease-resistant prion protein formation by porphyrins and
phthalocyanines. Proc Natl Acad Sci USA 95: 12117–12122, 1998.
105. Chandler RL. Encephalopathy in mice produced by inoculation
with scrapie brain material. Lancet 1: 1378–1379, 1961.
106. Chazot G, Broussolle E, Lapras C, Blättler T, Aguzzi A, Kopp
N. New variant of Creutzfeldt-Jakob disease in a 26-year-old French
man. Lancet 347: 1181, 1996.
107. Chesebro B, Race R, Wehrly K, Nishio J, Bloom M, Lechner D,
Bergstrom S, Robbins K, Mayer L, Keith JM. Identification of
scrapie prion protein-specific mRNA in scrapie-infected and uninfected
brain. Nature 315: 331–333, 1985.
108. Chesebro B, Trifilo M, Race R, Meade-White K, Teng C,
LaCasse R, Raymond L, Favara C, Baron G, Priola S, Caughey
B, Masliah E, Oldstone M. Anchorless prion protein results in
infectious amyloid disease without clinical scrapie. Science 308:
1435–1439, 2005.
109. Chiesa R, Piccardo P, Ghetti B, Harris DA. Neurological illness
in transgenic mice expressing a prion protein with an insertional
mutation. Neuron 21: 1339–1351, 1998.
110. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and
human disease. Annu Rev Biochem 75: 333–366, 2006.
111. Clarke MC, Kimberlin RH. Pathogenesis of mouse scrapie: distribution
of agent in the pulp and stroma of infected spleens. Vet
Microbiol 9: 215–225, 1984.
112. Clarke MC, Millson GC. Infection of a cell line of mouse L
fibroblasts with scrapie agent. Nature 261: 144–145, 1976.
113. Clouscard C, Beaudry P, Elsen JM, Milan D, Dussaucy M,
Bounneau C, Schelcher F, Chatelain J, Launay JM, Laplanche
JL. Different allelic effects of the codons 136 and 171 of the prion
protein gene in sheep with natural scrapie. J Gen Virol 76: 2097–
2101, 1995.
114. Cohen AS, Shirahama T, Skinner M. Electron microscopy of
amyloid. In: Electron Microscopy of Proteins, edited by Harris JR.
New York: Academic, 1982, p. 165–206.
115. Cole S, Kimberlin RH. Pathogenesis of mouse scrapie: dynamics
of vacuolation in brain and spinal cord after intraperitoneal infection.
Neuropathol Appl Neurobiol 11: 213–227, 1985.
116. Collinge J. Molecular neurology of prion disease. J Neurol Neurosurg
Psychiatry 76: 906–919, 2005.
117. Collinge J, Palmer MS, Dryden AJ. Genetic predisposition to
iatrogenic Creutzfeldt-Jakob disease. Lancet 337: 1441–1442, 1991.
118. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF. Molecular
analysis of prion strain variation and the aetiology of “new variant”
CJD. Nature 383: 685–690, 1996.
119. Collinge J, Whitfield J, McKintosh E, Beck J, Mead S, Thomas
DJ, Alpers MP. Kuru in the 21st century–an acquired human prion
disease with very long incubation periods. Lancet 367: 2068–2074,
2006.
120. Collinge J, Whittington MA, Sidle KC, Smith CJ, Palmer MS,
Clarke AR, Jefferys JG. Prion protein is necessary for normal
synaptic function. Nature 370: 295–297, 1994.
121. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters
CL. Quinacrine does not prolong survival in a murine Creutzfeldt-
Jakob disease model. Ann Neurol 52: 503–506, 2002.
122. Colombo G, Meli M, Morra G, Gabizon R, Gasset M. Methionine
sulfoxides on prion protein Helix-3 switch on the alpha-fold
destabilization required for conversion. PLoS ONE 4: e4296, 2009.
123. Cooper E. Quinacrine in possible or probable CJD: it is blinded
investigators, not patients, who must be in equipoise over treatment.
BMJ 324: 239, 2002.
124. Costa PP, Figueira AS, Bravo FR. Amyloid fibril protein related
to prealbumin in familial amyloidotic polyneuropathy. Proc Natl
Acad Sci USA 75: 4499–4503, 1978.
125. Cousens SN, Harries Jones R, Knight R, Will RG, Smith PG,
Matthews WB. Geographical distribution of cases of Creutzfeldt-